Effect of thalidomide combined with CHOP on immune function, angiogenesis and inflammatory factors in patients with diffuse large B-cell lymphoma

• Main Authors: Yun Wan, Yu-gang Xing, Liang-hua Wang, An-wei Dai
• Format: Article
• Language: English
• Published: Editorial Board of Journal of Hainan Medical University 2019-09-01
• Series: Journal of Hainan Medical University
• Subjects: thalidomide; diffuse large b b-cell lymphoma; immune function; vegf; inflammatory cytokines
• Online Access: http://www.hnykdxxb.com/PDF/201918/5.pdf

Objective: To mainly explore the effect of thalidomide combined with CHOP chemotherapy regimen on immunoglobulin, VEGF, lactate dehydrogenase, inflammatory factors and other related factors in patients with diffuse large B-cell lymphoma. Methods: A total of 83 patients with diffuse large B-cell lymphoma admitted to the Department of Hematology and Oncology in our hospital from December 2012 to December 2018 were collected. CHOP chemotherapy was given to 40 patients in the chemotherapy group. And 43 patients in the thalidomide group were treated with thalidomide combined with CHOP chemotherapy. Immunoglobulin IgG, IgA, IgM, vascular endothelial growth factor (VEGF), tumor necrosis factor (TNF-α), lactate dehydrogenase (LDH), β2 microglobulin (β2-MG), Th17 cell ratio and natural killer cell (NK) ratio were measured before and after treatment. Results: There were no significant differences in immunoglobulin, inflammatory cytokines and other related factors between the two groups before treatment (P>0.05). After 6 cycles of treatment, the levels of immunoglobulin IgG, IgA, IgM, VEGF, LDH, β2-MG and the ratio of NK cells in the chemotherapy group were significantly lower than those before treatment (P<0.05); TNF-α and the ratio of Th17 cells were significantly higher than that those before treatment. The levels of IgG, IgA, IgM, VEGF, LDH and β2-MG in the thalidomide group were significantly lower than those before treatment (P<0.05). The levels of TNF-α, Th17 cells and NK cell rates were significantly higher than those before treatment (P<0.05). In addition, the levels of IgG, IgA, IgM, VEGF, LDH and β2-MG in the thalidomide group were significantly lower than those in the chemotherapy group (P<0.05), and the level of TNF-α, the rates of Th17 cells and NK cells were significantly higher than those in the chemotherapy group (P<0.05). Conclusion: Thalidomide combined with CHOP chemotherapy has a significant therapeutic effect on diffuse large B-cell lymphoma. Thalidomide combined with CHOP chemotherapy can significantly reduce the levels of angiogenesis VEGF, lactate dehydrogenase and β2-MG in patients, significantly regulate the immune function of patients, and improve the Th17 cell rate and natural killer cell rate and the level of TNF-α in the body. This article provides the basis for the treatment of clinical diffuse large B cell lymphoma.